ODE (Office of Device Evaluation) adds third deputy director in reorganisation:
This article was originally published in Clinica
A reorganisation is in store for the Office of Device Evaluation (ODE) at the US FDA's Center for Devices and Radiological Health now that Susan Alpert has left to work at the FDA's food centre. The agency is advertising for a third deputy director to assist the new director, who has not yet been appointed. Dr Alpert shared the oversight responsibilities for the centre's six review divisions with Kimber Richter, deputy director for science and regulatory policy. The other deputy, Phil Phillips, handled regulatory matters. By adding a second clinical deputy, CDRH director David Feigal aims to relieve the next ODE director of some of the workload. ODE is responsible for product reviews.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.